Business Inquiry

Global：

Email:marketing@medicilon.com

+1(781)535-1428(U.S.)

0044 7790 816 954 (Europe)

China：

Email: marketing@medicilon.com.cn

Tel: +86 (21) 5859-1500

Farnesyltransferase inhibitor LNK-754 could rapidly cross the blood-brain-barrier after a single oral dose. Pharmacokinetic analysis was performed by Medicilon

2023-07-11

Page View：

Age-related neurodegenerative disorders are characterized by the progressive accumulation of misfolded and aggregated proteins. SNARE protein ykt6 plays a crucial role in proteostasis and lysosomal function by enhancing hydrolase trafficking under stressful conditions. Activating ykt6 by small-molecule farnesyltransferase inhibitors (FTIs) restores lysosomal activity and reduces a-synuclein in patient-derived neurons and mice. Pharmacokinetic studies revealed that after a single oral dose, the FTI (LNK-754) was cleared from plasma within 20 hours and could rapidly cross the blood-brain-barrier. Pharmacokinetic analysis was performed as a service provided by Medicilon.

Reference:

Leah K Cuddy, et al. Stress-Induced Cellular Clearance Is Mediated by the SNARE Protein ykt6 and Disrupted by α-Synuclein. Neuron. 2019 Dec 4;104(5):869-884.e11. doi: 10.1016/j.neuron.2019.09.001.

neurodegenerative-disorders Pharmacokinetic-studies blood-brain-barrier

Return

Relevant News

Design and synthesis of selective orally bioavailable threonine tyrosine kinase (TTK) inhibitors. The pharmacokinetic studies were carried out by Medicilon

2023-07-11

Threonine tyrosine kinase (TTK), a dual-specificity protein kinase, acts as a core component of the spindle assembly checkpoint and plays a crucial role in accurate separation of sister chromatids during mitosis to avoid aneuploidy. TTK inhibition is an attractive wide-spectrum strategy for cancer therapy. Researchers designed and synthesized a series of pyrido[2, 3-d]pyrimidin-7(8H)-ones as new selective orally bioavailable TTK inhibitors. All the pharmacokinetic studies were carried out by Medicilon. Compounds 5o exhibits strong binding affinity to TTK with a Kd value of 0.15 nM. Compound 5o demonstrates good oral pharmacokinetic properties.

QF-036 is an HIV-1 maturation inhibitor in preclinical development with favourable pharmacokinetic properties. The pharmacokinetic studies were performed by Medicilon

2023-07-11

QF-036 is an HIV-1 maturation inhibitor in preclinical development. After oral QF-036 administration to rats and monkeys, both species exhibit moderate bioavailability, and the plasma drug exposure increased in an approximately dose-proportional manner. The favourable viral inhibitory activity and pharmacokinetic properties provide critical support for QF-036 as a promising anti-HIV therapeutic candidate. The pharmacokinetic studies were performed by Medicilon.

A simple and accurate liquid chromatography coupled with tandem mass spectrometry method was developed for determination and in vivo pharmacokinetic studies of vitexin rhamnoside in rat plasma

2023-07-11

A simple and accurate liquid chromatography coupled with tandem mass spectrometry method was developed for determination and in vivo pharmacokinetic studies of vitexin rhamnoside in rat plasma. Practical utility of this new LC/MS/MS method was confirmed in pilot pharmacokinetic studies in rats following both intravenous and oral administration. Animal studies were carried out in Medicilon.